Security
Replimune Group, Inc. Common Stock · REPL
REPLNASDAQCommon stockCurrentCIK 1737953Updated Nov 3, 2026
REPL price & chart
Loading TradingView…
NASDAQ:REPL on TradingView ↗About the company
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is intended to ignite local activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to then activate a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
In the news
REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact Levi & Korsinsky ↗
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL ↗
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm ↗
Seeking Alpha
Replimune anticipates permanent J-code by April 2027 as TUDRIQEV launch metrics build ↗
Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript ↗
Replimune Group: A Hold Until TUDRIQEV's Commercial Potential Becomes Clear ↗
SEC disclosures
Replimune Group, Inc. files 8-K: Material Event ↗
Recent filings
4 filing
144 filing
144 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | Q1 2025 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 333,590,000Source | 603,628,000Source | 532,930,000Source | 389,450,000Source | 498,202,000Source | 252,447,000Source | 469,507,000Source | 534,965,000Source | 332,388,000Source | 551,328,000Source | 487,722,000Source | 646,591,000Source |
| Property, Plant and Equipment, NetUSD | 13,847,000Source | 13,616,000Source | 9,473,000Source | 14,711,000Source | 12,591,000Source | 11,858,000Source | 14,679,000Source | 11,403,000Source | 12,974,000Source | 13,739,000Source | 10,483,000Source | 7,479,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 122,951,000Source | 172,245,000Source | 97,672,000Source | 102,298,000Source | 113,494,000Source | 185,359,000Source | 97,373,000Source | 151,658,000Source | 209,024,000Source | 111,119,000Source | 74,457,000Source | 146,590,000Source |
| Assets, CurrentUSD | 280,354,000Source | 547,577,000Source | 479,164,000Source | 333,749,000Source | 442,635,000Source | 200,807,000Source | 413,371,000Source | 480,320,000Source | 279,119,000Source | 495,880,000Source | 433,667,000Source | 592,603,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 8,262,000Source | 7,972,000Source | 8,518,000Source | 8,299,000Source | 8,527,000Source | 5,479,000Source | 8,188,000Source | 6,263,000Source | 8,611,000Source | 8,351,000Source | 8,077,000Source | 6,278,000Source |
| Operating Lease, Right-of-Use AssetUSD | 3,498,000Source | 4,120,000Source | 4,813,000Source | 3,692,000Source | 4,417,000Source | 3,068,000Source | 3,918,000Source | 4,475,000Source | 3,270,000Source | 3,998,000Source | 4,635,000Source | 5,208,000Source |
| Other Assets, NoncurrentUSD | 1,200,000Source | 1,200,000Source | — | 1,200,000Source | — | 3,238,000Source | 1,200,000Source | — | 2,942,000Source | 1,200,000Source | — | — |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 123,051,000Source | 121,254,000Source | 111,393,000Source | 126,114,000Source | 116,743,000Source | 146,802,000Source | 132,792,000Source | 108,514,000Source | 166,228,000Source | 135,485,000Source | 113,214,000Source | 91,299,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 79,000Source | 77,000Source | 61,000Source | 78,000Source | 68,000Source | 84,000Source | 78,000Source | 68,000Source | 82,000Source | 77,000Source | 61,000Source | 57,000Source |
| Additional Paid in CapitalUSD | 1,394,198,000Source | 1,350,587,000Source | 1,062,949,000Source | 1,376,507,000Source | 1,185,866,000Source | 1,431,870,000Source | 1,367,668,000Source | 1,177,113,000Source | 1,423,194,000Source | 1,358,897,000Source | 1,070,874,000Source | 1,034,994,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,189,302,000Source | -874,449,000Source | -646,207,000Source | -1,118,372,000Source | -808,109,000Source | -1,332,285,000Source | -1,035,272,000Source | -755,054,000Source | -1,262,519,000Source | -948,579,000Source | -701,282,000Source | -485,488,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 5,564,000Source | 6,159,000Source | 4,734,000Source | 5,123,000Source | 3,634,000Source | 5,976,000Source | 4,241,000Source | 4,324,000Source | 5,403,000Source | 5,448,000Source | 4,855,000Source | 5,729,000Source |
| Stockholders' Equity Attributable to ParentUSD | 210,539,000Source | 482,374,000Source | 421,537,000Source | 263,336,000Source | 381,459,000Source | 105,645,000Source | 336,715,000Source | 426,451,000Source | 166,160,000Source | 415,843,000Source | 374,508,000Source | 555,292,000Source |
| Liabilities and EquityUSD | 333,590,000Source | 603,628,000Source | 532,930,000Source | 389,450,000Source | 498,202,000Source | 252,447,000Source | 469,507,000Source | 534,965,000Source | 332,388,000Source | 551,328,000Source | 487,722,000Source | 646,591,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 50,087,000Source | 47,890,000Source | 38,650,000Source | 52,900,000Source | 43,790,000Source | 38,412,000Source | 59,564,000Source | 35,680,000Source | 58,228,000Source | 62,362,000Source | 40,438,000Source | 33,825,000Source |
| Operating Lease, Liability, CurrentUSD | 1,213,000Source | 1,164,000Source | 1,163,000Source | 1,210,000Source | 1,199,000Source | 1,136,000Source | 1,220,000Source | 1,164,000Source | 1,158,000Source | 1,184,000Source | 1,161,000Source | 1,118,000Source |
| Accounts Payable, CurrentUSD | 5,647,000Source | 7,188,000Source | 3,903,000Source | 6,404,000Source | 8,410,000Source | 4,261,000Source | 15,483,000Source | 864,000Source | 6,671,000Source | 12,463,000Source | 2,578,000Source | 5,364,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,514,000Source | 3,225,000Source | 3,955,000Source | 2,723,000Source | 3,502,000Source | 2,136,000Source | 2,953,000Source | 3,600,000Source | 2,328,000Source | 3,076,000Source | 3,771,000Source | 4,389,000Source |
| Other Liabilities, NoncurrentUSD | 693,000Source | 1,266,000Source | 793,000Source | 941,000Source | 786,000Source | 455,000Source | 941,000Source | 786,000Source | 455,000Source | 941,000Source | 786,000Source | 472,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 47,628,000Source | 45,960,000Source | — | 47,206,000Source | 45,572,000Source | 84,114,000Source | 46,792,000Source | 45,192,000Source | 83,308,000Source | 46,377,000Source | 44,809,000Source | 28,648,000Source |
| Short-term InvestmentsUSD | 146,186,000Source | 364,294,000Source | 368,679,000Source | 221,346,000Source | 318,565,000Source | 9,969,000Source | 305,967,000Source | 317,466,000Source | 59,865,000Source | 372,685,000Source | 346,211,000Source | 436,796,000Source |
cash flow · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -69,766,000Source | -86,693,000Source | -313,940,000Source | -247,297,000Source | -215,794,000Source | -174,284,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 800,000Source | 1,000,000Source | 800,000Source | 900,000Source | 937,000Source | 873,000Source | 3,332,000Source | 3,502,000Source | 2,655,000Source | 2,447,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 7,674,000Source | 8,762,000Source | 32,272,000Source | 35,044,000Source | 34,125,000Source | 28,131,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -2,334,000Source | 3,765,000Source | -4,939,000Source | 9,941,000Source | -2,794,000Source | 1,981,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -75,728,000Source | -77,016,000Source | -280,344,000Source | -192,250,000Source | -185,467,000Source | -128,050,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 49,993,000Source | 65,048,000Source | 310,843,000Source | -23,796,000Source | 97,201,000Source | -142,502,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 2,270,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 800,000Source | -158,000Source | 66,294,000Source | 252,396,000Source | 16,283,000Source | 311,303,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -23,665,000Source | -13,742,000Source | 97,905,000Source | 36,665,000Source | -72,069,000Source | 40,642,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 124,655,000Source | 173,945,000Source | 104,003,000Source | 115,199,000Source | 187,062,000Source | 99,080,000Source | 210,727,000Source | 112,822,000Source | 76,157,000Source | 148,226,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,775,000Source | 1,059,000Source | 4,688,000Source | 4,198,000Source | 3,044,000Source | 1,066,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 33,000Source | 0Source | -5,000Source | 105,000Source | 300,000Source | 0Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | 1,270,000Source | -1,616,000Source | 1,112,000Source | 315,000Source | -86,000Source | -109,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 7,047,000Source | 8,639,000Source | 8,338,000Source | 8,650,000Source | 7,674,000Source | 8,762,000Source | 32,272,000Source | 35,044,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | 688,000Source | -591,000Source | 942,000Source | 201,000Source | 771,000Source | -5,676,000Source |
| General and Administrative ExpenseUSD | — | — | 18,728,000Source | 18,015,000Source | 26,414,000Source | 15,468,000Source | — | 32,579,000Source | — | 72,180,000Source | 59,810,000Source | 50,553,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | -314,491,000Source | -246,829,000Source | -215,386,000Source | -173,996,000Source |
| Income Tax Expense (Benefit)USD | — | — | -311,000Source | 575,000Source | 0Source | 0Source | — | 0Source | -551,000Source | 468,000Source | 408,000Source | 288,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -70,930,000Source | -66,340,000Source | -83,100,000Source | -53,055,000Source | -69,766,000Source | -86,693,000Source | -313,940,000Source | -247,297,000Source | -215,794,000Source | -174,284,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -70,930,000Source | -66,340,000Source | -83,100,000Source | -53,055,000Source | -69,766,000Source | -86,693,000Source | -313,940,000Source | -247,297,000Source | -215,794,000Source | -174,284,000Source |
| Nonoperating Income (Expense)USD | — | — | 627,000Source | 254,000Source | 1,191,000Source | 5,861,000Source | -1,519,000Source | 3,729,000Source | 5,428,000Source | 14,798,000Source | 19,387,000Source | 3,084,000Source |
| Operating ExpensesUSD | — | — | 71,868,000Source | 66,019,000Source | 84,291,000Source | 58,916,000Source | 68,247,000Source | 90,422,000Source | 319,919,000Source | 261,627,000Source | 234,773,000Source | 177,080,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -580,000Source | -3,281,000Source | -876,000Source | 2,028,000Source | -688,000Source | 591,000Source | -942,000Source | -202,000Source | 771,000Source | -5,676,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | — | 155,728,000Source | 0Source | 149,854,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | — | — | — | — | — | — | — | 35,000,000Source | 0Source | 15,000,000Source | 28,154,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,003,000Source | 8,000Source | 883,000Source | 267,000Source | 1,759,000Source | 3,444,000Source |
| Capitalized Computer Software, Amortization | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2026 | Q4 2025 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2027 | Q1 2026 | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General and Administrative ExpenseUSD | — | — | — | — | — | — | 18,970,000Source | 32,579,000Source | 98,735,000Source | — | — | — |
| Operating Income (Loss)USD | — | — | -71,868,000Source | -66,019,000Source | -84,291,000Source | -58,916,000Source | -68,247,000Source | -90,422,000Source | -319,919,000Source | -261,627,000Source | -234,773,000Source | -177,080,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -580,000Source | -3,281,000Source | -876,000Source | 2,028,000Source | -688,000Source | 591,000Source | -942,000Source | -202,000Source | 771,000Source | -5,676,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -71,241,000Source | -65,765,000Source | — | -53,055,000Source | — | — | -314,491,000Source | -246,829,000Source | -215,386,000Source | -173,996,000Source |
| Income Tax Expense (Benefit)USD | — | — | -311,000Source | 575,000Source | 0Source | 0Source | — | 0Source | -551,000Source | 468,000Source | 408,000Source | 288,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -70,930,000Source | -66,340,000Source | -83,100,000Source | -53,055,000Source | -69,766,000Source | -86,693,000Source | -313,940,000Source | -247,297,000Source | -215,794,000Source | -174,284,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.77Source | -0.79Source | -0.9Source | -0.68Source | -0.72Source | -0.95Source | -3.38Source | -3.07Source | -3.24Source | -2.99Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.77Source | -0.79Source | -0.9Source | -0.68Source | -0.72Source | -0.95Source | -3.38Source | -3.07Source | -3.24Source | -2.99Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 92,187,581Source | 83,498,892Source | 91,915,769Source | 78,570,135Source | 96,864,452Source | 91,516,199Source | 92,803,711Source | 80,564,147Source | 66,569,894Source | 58,213,010Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 92,187,581Source | 83,498,892Source | 91,915,769Source | 78,570,135Source | 96,864,452Source | 91,516,199Source | 92,803,711Source | 80,564,147Source | 66,569,894Source | 58,213,010Source |
| Additional Financial Items | ||||||||||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | 688,000Source | -591,000Source | 942,000Source | 201,000Source | 771,000Source | -5,676,000Source |
| General and Administrative ExpenseUSD | — | — | 18,728,000Source | 18,015,000Source | 26,414,000Source | 15,468,000Source | — | 32,579,000Source | — | 72,180,000Source | 59,810,000Source | 50,553,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | — | — | — | — | — | — | — | -314,491,000Source | -246,829,000Source | -215,386,000Source | -173,996,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -66,042,000Source | -25,870,000Source | -19,367,000Source | -18,367,000Source |
| Interest Expense, DebtUSD | — | — | 1,466,000Source | 1,450,000Source | 1,488,000Source | 1,438,000Source | 2,581,000Source | 1,475,000Source | 6,796,000Source | 5,775,000Source | 4,497,000Source | 1,963,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -70,930,000Source | -66,340,000Source | -83,100,000Source | -53,055,000Source | -69,766,000Source | -86,693,000Source | -313,940,000Source | -247,297,000Source | -215,794,000Source | -174,284,000Source |
| Nonoperating Income (Expense)USD | — | — | 627,000Source | 254,000Source | 1,191,000Source | 5,861,000Source | -1,519,000Source | 3,729,000Source | 5,428,000Source | 14,798,000Source | 19,387,000Source | 3,084,000Source |
| Operating ExpensesUSD | — | — | 71,868,000Source | 66,019,000Source | 84,291,000Source | 58,916,000Source | 68,247,000Source | 90,422,000Source | 319,919,000Source | 261,627,000Source | 234,773,000Source | 177,080,000Source |
| Research and Development ExpenseUSD | — | — | 53,140,000Source | 48,004,000Source | 57,877,000Source | 43,448,000Source | 49,277,000Source | 57,843,000Source | 221,184,000Source | 189,447,000Source | 174,963,000Source | 126,527,000Source |
| Capitalized Computer Software, Amortization | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-298356
Registration 333-287537
Filing attachments
tm2628395d1_ex99-1.htm · 8-K · 2026-10-28
Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET Woburn, MA, October 28, 2026 - Replimune Group, Inc. (Nasdaq: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for …
Read attachment ↗tm2621843d2_ex4-13.htm · S-3ASR · 2026-08-14
Exhibit 4.13 REPLIMUNE GROUP, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [· ] (subject to adjustment) Warrant No. [·] Original Issue Date: [·], 2026 Replimune Group, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [· ] or its registered assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Co…
Read attachment ↗tm2621843d2_ex4-9.htm · S-3ASR · 2026-08-14
Exhibit 4.9 REPLIMUNE GROUP, Inc. INDENTURE Dated as of [●] [●] Trustee TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS SECTION 1.01. Certain Terms Defined 1 SECTION 1.02. Other Definitions 5 SECTION 1.03. Rules of Construction 5 ARTICLE 2 SECURITY FORMS SECTION 2.01. Forms Generally …
Read attachment ↗tm2623208d1_ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 tm2623208d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV™ in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends cash runway to support commercial launch and confirmatory trial Woburn, MA, August 14, 2026 - Replimune Group, Inc. (Nasdaq: REPL), a commerc…
Read attachment ↗tm2622780d1_ex4-1.htm · 8-K/A · 2026-08-11
EX-4.1 2 tm2622780d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 REPLIMUNE GROUP, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2026 Replimune Group, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “Holder”), is entitled, subject to the te…
Read attachment ↗tm2622673d1_ex4-1.htm · 8-K · 2026-08-10
EX-4.1 3 tm2622673d1_ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 REPLIMUNE GROUP, INC. FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [●] (subject to adjustment) Warrant No. [●] Original Issue Date: [●], 2026 Replimune Group, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●] or its registered assigns (the “Holder”), is entitled, subject to the te…
Read attachment ↗